{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T03:33:39Z","timestamp":1784604819493,"version":"3.55.0"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:sec>\n            <jats:title>Objectives:<\/jats:title>\n            <jats:p>Clinical concerns about hematologic toxicities in human immunodeficiency virus (HIV)+ patients with squamous cell anal cancer (SCAC) may lead to de-escalation of treatment intensity. The objective of this study is to evaluate clinical outcomes including toxicity following standard concurrent curative-intent chemoradiation for HIV+ and HIV\u2212 patients with SCAC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Materials and Methods:<\/jats:title>\n            <jats:p>Among 97 evaluable patients treated between 2009 and 2016 (median age 52.2\u2009y), 43 (44.3%) were HIV+ and 54 (55.7%) HIV\u2212. The majority of the radiation was delivered using intensity-modulated radiation therapy and chemotherapy consisting primarily (93%) of 5-fluorouracil and mitomycin C. Clinical outcomes assessed included toxicity, locoregional control (LRC), distant metastasis (DM), progression-free survival (PFS), colostomy-free survival (CFS), overall survival (OS), and cause-specific survival (CSS).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>With a median follow-up of 45 months, HIV+ patients exhibited a trend toward reduced OS compared with HIV\u2212 patients (4\u2009y OS 61.2% vs. 78.3%; HR 2.09; 95% CI, 0.97-4.52; <jats:italic toggle=\"yes\">P<\/jats:italic>=0.055) on univariable analysis, but HIV status was not significant after adjusting for additional parameters on multivariable analysis. Toxicity rates, LRC, CFS, PFS, freedom from DM, and CSS were similar between the 2 cohorts. On multivariable analysis, tumor size &gt;5\u2009cm impacted all clinical outcomes (trend for LRC) except CFS. Radiation treatment extension beyond 7 days was found to negatively impact LRC and CSS. Male sex was associated with worse CFS.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Radiation therapy with concurrent 5-fluorouracil and mitomycin C chemotherapy is reasonably well-tolerated as curative treatment for HIV+ patients with SCAC, and no significant difference in outcomes was noted relative to HIV\u2212 patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/coc.0000000000000736","type":"journal-article","created":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T09:00:24Z","timestamp":1595322024000},"page":"701-708","source":"Crossref","is-referenced-by-count":4,"title":["Feasibility and Outcome of Routine Use of Concurrent Chemoradiation in HIV-positive Patients With Squamous Cell Anal Cancer"],"prefix":"10.1097","volume":"43","author":[{"given":"Andrew J.","family":"Leiker","sequence":"first","affiliation":[{"name":"Radiation Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiachien J.","family":"Wang","sequence":"additional","affiliation":[{"name":"Willis-Knighton Cancer Center, Monroe, LA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina N.","family":"Sanford","sequence":"additional","affiliation":[{"name":"Radiation Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd A.","family":"Aguilera","sequence":"additional","affiliation":[{"name":"Radiation Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sirisha","family":"Karri","sequence":"additional","affiliation":[{"name":"Department of Oncology, Kaiser Permanente, Sacramento, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad S.","family":"Beg","sequence":"additional","affiliation":[{"name":"Hematology Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed A.","family":"Kazmi","sequence":"additional","affiliation":[{"name":"Hematology Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Olson","sequence":"additional","affiliation":[{"name":"Surgery, University of Texas Southwestern Medical Center, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joselin A.","family":"Matthews","sequence":"additional","affiliation":[{"name":"Surgery, University of Texas Southwestern Medical Center, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abier","family":"Abdelnaby","sequence":"additional","affiliation":[{"name":"Surgery, University of Texas Southwestern Medical Center, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey J.","family":"Meyer","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Folkert","sequence":"additional","affiliation":[{"name":"Radiation Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,7,17]]},"reference":[{"key":"R1-20230903","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"R2-20230903","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1200\/JCO.2012.45.2524","article-title":"Changing patterns of anal canal carcinoma in the United States","volume":"31","author":"Nelson","year":"2013","journal-title":"J Clin Oncol"},{"key":"R3-20230903","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S1470-2045(12)70080-3","article-title":"Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis","volume":"13","author":"Machalek","year":"2012","journal-title":"Lancet Oncol"},{"key":"R4-20230903","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/jnci\/djq001","article-title":"Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2\/3: critical role of duration of infection","volume":"102","author":"Rodriguez","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"R5-20230903","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1200\/JCO.1997.15.5.2040","article-title":"Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups","volume":"15","author":"Bartelink","year":"1997","journal-title":"J Clin Oncol"},{"key":"R6-20230903","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1200\/JCO.1996.14.9.2527","article-title":"Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study","volume":"14","author":"Flam","year":"1996","journal-title":"J Clin Oncol"},{"key":"R7-20230903","doi-asserted-by":"crossref","first-page":"4344","DOI":"10.1200\/JCO.2012.43.8085","article-title":"Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil\/mitomycin versus fluorouracil\/cisplatin","volume":"30","author":"Gunderson","year":"2012","journal-title":"J Clin Oncol"},{"key":"R8-20230903","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/sj.bjc.6605605","article-title":"Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I)","volume":"102","author":"Northover","year":"2010","journal-title":"Br J Cancer"},{"key":"R9-20230903","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1093\/cid\/cir1012","article-title":"Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America","volume":"54","author":"Silverberg","year":"2012","journal-title":"Clin Infect Dis"},{"key":"R10-20230903","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/S0140-6736(94)92636-0","article-title":"High incidence of anal cancer among AIDS patients. The AIDS\/Cancer Working Group","volume":"343","author":"Melbye","year":"1994","journal-title":"Lancet"},{"key":"R11-20230903","first-page":"34","article-title":"HIV-positive anal cancer: an update for the clinician","volume":"1","author":"Dandapani","year":"2010","journal-title":"J Gastrointest Oncol"},{"key":"R12-20230903","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1158\/1055-9965.EPI-14-0146","article-title":"Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis","volume":"23","author":"Templeton","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R13-20230903","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0140-6736(96)03409-5","article-title":"Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research","volume":"348","year":"1996","journal-title":"Lancet"},{"key":"R14-20230903","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1001\/jama.299.16.1914","article-title":"Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial","volume":"299","author":"Ajani","year":"2008","journal-title":"JAMA"},{"key":"R15-20230903","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S1470-2045(13)70086-X","article-title":"Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 x 2 factorial trial","volume":"14","author":"James","year":"2013","journal-title":"Lancet Oncol"},{"key":"R16-20230903","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1200\/JCO.2011.35.4837","article-title":"Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial","volume":"30","author":"Peiffert","year":"2012","journal-title":"J Clin Oncol"},{"key":"R17-20230903","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/S1470-2045(09)70282-7","article-title":"Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study","volume":"10","author":"Guiguet","year":"2009","journal-title":"Lancet Oncol"},{"key":"R18-20230903","doi-asserted-by":"crossref","first-page":"4360","DOI":"10.1200\/JCO.2012.44.5486","article-title":"Incidence of HIV-related anal cancer remains increased despite long-term combined antiretroviral treatment: results from the French hospital database on HIV","volume":"30","author":"Piketty","year":"2012","journal-title":"J Clin Oncol"},{"key":"R19-20230903","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1200\/JCO.2016.69.1642","article-title":"Cetuximab plus chemoradiotherapy for HIV-associated anal carcinoma: a phase II AIDS malignancy consortium trial","volume":"35","author":"Sparano","year":"2017","journal-title":"J Clin Oncol"},{"key":"R20-20230903","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1200\/JCO.2014.59.5967","article-title":"Elevated cancer-specific mortality among HIV-infected patients in the United States","volume":"33","author":"Coghill","year":"2015","journal-title":"J Clin Oncol"},{"key":"R21-20230903","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1200\/JCO.2007.14.2810","article-title":"Human immunodeficiency virus-associated squamous cell cancer of the anus: epidemiology and outcomes in the highly active antiretroviral therapy era","volume":"26","author":"Chiao","year":"2008","journal-title":"J Clin Oncol"},{"key":"R22-20230903","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1200\/JCO.2007.15.2348","article-title":"HIV-specific differences in outcome of squamous cell carcinoma of the anal canal: a multicentric cohort study of HIV-positive patients receiving highly active antiretroviral therapy","volume":"26","author":"Oehler-Janne","year":"2008","journal-title":"J Clin Oncol"},{"key":"R23-20230903","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.radonc.2010.11.011","article-title":"Concurrent chemoradiotherapy with 5-fluorouracil and mitomycin C for anal carcinoma: are there differences between HIV-positive and HIV-negative patients in the era of highly active antiretroviral therapy?","volume":"98","author":"Fraunholz","year":"2011","journal-title":"Radiother Oncol"},{"key":"R24-20230903","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1258\/ijsa.2011.011020","article-title":"Evaluation of the impact of HIV serostatus, tobacco smoking and CD4 counts on epidermoid anal cancer survival","volume":"23","author":"Linam","year":"2012","journal-title":"Int J STD AIDS"},{"key":"R25-20230903","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ijrobp.2008.10.046","article-title":"Outcomes of chemoradiotherapy with 5-fluorouracil and mitomycin C for anal cancer in immunocompetent versus immunodeficient patients","volume":"75","author":"Seo","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R26-20230903","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/COC.0000000000000172","article-title":"Comparison of toxicity and treatment outcomes in HIV-positive versus HIV-negative patients with squamous cell carcinoma of the anal canal","volume":"40","author":"White","year":"2017","journal-title":"Am J Clin Oncol"},{"key":"R27-20230903","first-page":"135","article-title":"Squamous cell cancer of the anal canal in HIV-infected patients receiving highly active antiretroviral therapy: a single institution experience","volume":"34","author":"Hammad","year":"2011","journal-title":"Am J Clin Oncol"},{"key":"R28-20230903","doi-asserted-by":"crossref","DOI":"10.1634\/theoncologist.2019-0824","article-title":"Factors impacting differential outcomes in the definitive radiation treatment of anal cancer between HIV-positive and HIV-negative patients","author":"Susko","year":"2020","journal-title":"Oncologist"},{"key":"R29-20230903","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/annonc\/mdr050","article-title":"Chemoradiotherapy for anal cancer in HIV patients causes prolonged CD4 cell count suppression","volume":"23","author":"Alfa-Wali","year":"2012","journal-title":"Ann Oncol"},{"key":"R30-20230903","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S1470-2045(17)30104-3","article-title":"Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study","volume":"18","author":"Morris","year":"2017","journal-title":"Lancet Oncol"},{"key":"R31-20230903","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1200\/JCO.2008.19.6857","article-title":"US intergroup anal carcinoma trial: tumor diameter predicts for colostomy","volume":"27","author":"Ajani","year":"2009","journal-title":"J Clin Oncol"},{"key":"R32-20230903","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1093\/annonc\/mdu188","article-title":"Tumour- and treatment-related colostomy rates following mitomycin C or cisplatin chemoradiation with or without maintenance chemotherapy in squamous cell carcinoma of the anus in the ACT II trial","volume":"25","author":"Glynne-Jones","year":"2014","journal-title":"Ann Oncol"},{"key":"R33-20230903","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.ijrobp.2013.07.035","article-title":"Anal carcinoma: impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98-11 phase 3 trial","volume":"87","author":"Gunderson","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R34-20230903","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1002\/cncr.25188","article-title":"Prognostic factors derived from a prospective database dictate clinical biology of anal cancer: the intergroup trial (RTOG 98-11)","volume":"116","author":"Ajani","year":"2010","journal-title":"Cancer"},{"key":"R35-20230903","doi-asserted-by":"crossref","first-page":"5061","DOI":"10.1200\/JCO.2010.29.1351","article-title":"Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11","volume":"28","author":"Ben-Josef","year":"2010","journal-title":"J Clin Oncol"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/COC.0000000000000736","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T04:08:08Z","timestamp":1693714088000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/COC.0000000000000736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,17]]},"references-count":35,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/coc.0000000000000736","relation":{},"ISSN":["0277-3732"],"issn-type":[{"value":"0277-3732","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7,17]]}}}